QEL-005
Sponsors
Quell Therapeutics Limited
Conditions
Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic SclerosisDiffuse cutaneous systemic sclerosis (dcSSc)
Difficult to treat rheumatoid arthritis (D2TRA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)
Phase 1
Controlling Hyperactive Immunity With Long-lived Lymphocytes
RecruitingNCT07473154
Start: 2026-04-10End: 2028-08-01Target: 16Updated: 2026-08-21
A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
Not yet recruitingCTIS2025-523971-46-00
Target: 8Updated: 2026-04-22